In recent years, the use of PD-1 and PD-L1 checkpoint inhibitors have become the preferred immunotherapeutic strategy for melanoma [18], glioblastoma multiforme [19], and hepatocellular carcinoma [20]. The gene discussed is CD274; the disease is glioblastoma.